A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Clinical trial NCT05259917 · COMPLETED
Trial details
- NCT number
- NCT05259917
- Sponsor
- KalVista Pharmaceuticals, Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-22
- Primary completion
- 2023-12-31
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.